Selective serotonin reuptake inhibitor usage patterns as risk factors for hospitalization

Administration and Policy in Mental Health

Volumn 30, Issue 2, 2002, Pages 121-139

  Sheffield, Reinée E ^a,b   Lo Sasso, Anthony T ^c   Young, Christopher H ^d   Way, Karen ^e  

^a PFIZER INC   (United States)

^b Mail Code 034   (United States)

^c NORTHWESTERN UNIVERSITY   (United States)

^d Metrics and Analysis at AdvancePCS   (United States)

^e PCS Health Systems Incorporated   (United States)

Author keywords

Antidepressants; Augmentation; Early discontinuation; SSRI; Switching

Indexed keywords

AMPHETAMINE DERIVATIVE; FLUOXETINE; HYPNOTIC SEDATIVE AGENT; PAROXETINE; PSYCHOTROPIC AGENT; SEROTONIN UPTAKE INHIBITOR; SERTRALINE;

ADULT; AMBULATORY CARE; ANAMNESIS; ANXIETY DISORDER; ARTICLE; BIPOLAR DISORDER; CONSULTATION; CONTROLLED STUDY; DEPRESSION; DRUG CHOICE; DRUG UTILIZATION; DRUG WITHDRAWAL; FEMALE; HEALTH CARE POLICY; HEALTH MAINTENANCE ORGANIZATION; HOSPITALIZATION; HUMAN; LENGTH OF STAY; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; MEDICAL DECISION MAKING; PRESCRIPTION; PRIORITY JOURNAL; PSYCHIATRIC DIAGNOSIS; RETROSPECTIVE STUDY; RISK FACTOR; SEX DIFFERENCE; SEX RATIO; TREATMENT OUTCOME;

ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; DEPRESSIVE DISORDER; DRUG UTILIZATION REVIEW; FLUOXETINE; HEALTH MAINTENANCE ORGANIZATIONS; HOSPITALIZATION; HUMANS; MEDICAL AUDIT; MIDWESTERN UNITED STATES; PAROXETINE; RETROSPECTIVE STUDIES; RISK FACTORS; SEROTONIN UPTAKE INHIBITORS; SERTRALINE;

EID: 0036872405     PISSN: 0894587X     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1022533118031     Document Type: Article

References (16)

1. Agency for Health Care Policy and Research. (1993). Clinical practice guideline number 5: Depression in primary care: Volume 2. Treatment of major depression. AHCPR Publication No. 93-0551; pp. 27-33. Rockville, MD: U.S. Department of Health and Human Services.
2. Croghan, T.W., Lair, TJ., Engelhart, L., Crown, W.E., Copley-Merriman, C., Melfi, C.A., Obenchain, R.L., & Buesching, D.P. (1997). Effect of antidepressant therapy on health care utilization and costs in primary care. Psychiatric Services, 48, 1420-1426.
3. Crown, W.H., Hylan, T.R., & Meneades, L. (1998). Antidepressant selection and use and healthcare expenditures: An empirical approach. Pharmacoeconomics, 13(4), 435-448.
4. Frank, R.G., Busch, S.H., & Berndt, E.R. (1998). Measuring prices and quantities of treatment for depression. American Economic Review, 88(2), 106-111.
5. Greenberg, P.E., Stiglin, L.E., Finkelstein, S.N., & Berndt, E.R. (1993). The economic burden of depression in 1990. Journal of Clinical Psychiatry, 54, 405-418.
6. Hylan, T.R., Crown, W.H., Meneades, L., Heiligenstein, J.H., Melfi, C.A., Croghan, T.W., & Buesching, D.P. (1999). SSRI Antidepressant drug use patterns in the naturalistic setting: A multivariate analysis. Medical Care, 37, AS36-AS44.
7. Kessler, R.C., McGonagle, K.A., Zhao, S., Nelson, C.B., Hughes, M., Eshleman, S., Wittchen, H.U., & Kendler, K.S. (1994). Life-time and 12-month prevalence of DSM-III-R psychiatric disorders in the United States: Results from the National Comorbidity Survey. Archives of General Psychiatry, 51, 8-19.
8. Regier, D.A., Narrow, W.E., Rae, D.S., Manderscheid, R.W., Locke, B.Z., & Goodwin, F.K. (1993). The de facto US mental and addictive disorders service system: Epidemiologic catchment area prospective 1-year prevalence rates of disorders and services. Archives of General Psychiatry, 50, 84-94.
9. Russell, J.M., Berndt, E.R., Miceli, R., Colucci, S., & Grudzinski, A.N. (1999). Course and cost of treatment for depression with fluoxetine, paroxetine and sertraline. American Journal of Managed Care, 5, 597-606.
10. Sclar, D.A., Robison, L.M., Skaer, T.L., Galin, R.S., Legg, R.F., Nemec, N.L., Hughes, T.E., Buesching, D.P., & Morgan, M. (1995). Antidepressant pharmacotherapy: Economic evaluation of fluoxetine, paroxetine and sertraline in a health maintenance organization. Journal of Internal Medicine Research, 23, 395-412.
11. Sclar, D.A., Robison, L.M., Skaer, T.L., Legg, R.F., Nemec, N.L., Galin, R.S., Hughes, T.E., & Buesching, D.P. (1994). Antidepressant pharmacotherapy: Economic outcomes in a health maintenance organization. Clinical Therapeutics, 16(4), 715-730.
12. Shapiro, S., Skinner, E.A., Kessler, L.G., Von Korff, M., German, P.S., Tischler, G.L., Leaf, PJ., Benham, L., Cottler, L., & Regier, D.A. (1984). Utilization of health and mental health services: Three epidemiological catchment area sites. Archives of General Psychiatry, 41, 971-978.
13. Simon, G.E., & Fishman, P. (1998). Cost implications of initial antidepressant selection in primary care. Pharmacoeconomics, 13(1, Pt. 1), 61-70.
14. Simon, G.E., Von Korff, M., Heiligenstein,J.H., Revicki, D.A., Grothaus, L., Katon, W., & Wagner, E.H. (1996). Initial antidepressant choice in primary care: Effectiveness and cost of fluoxetine vs. tricyclic antidepressants. Journal of the American Medical Association, 275, 1897-1902.
15. Thompson, D., Buesching, D., Gregor, K.J., & Oster, G. (1996). Patterns of antidepressant use and their relation to costs of care. American Journal of Managed Care, 2, 1239-1246.
16. Way, K., Young, C.H., Opland, E., Whitehouse, D., & Hughes, T. (1999). Antidepressant utilization patterns in a national managed care organization. Drug Benefit Trend, 11(9), 6-11.